

INPLASY PROTOCOL

To cite: Xie et al. Smoking status in the first line treatment of advanced EGFR-mutant non-small cell lung cancer : a network meta-analysis of randomized controlled trials. Inplasy protocol 2020100060. doi: 10.37766/inplasy2020.10.0060

Received: 17 October 2020

Published: 17 October 2020

Corresponding author:
Puyuan Xing

xingpuyuan@cicams.ac.cn

Author Affiliation:
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Support: None.

Review Stage at time of this submission: The review has not yet started.

Conflicts of interest: None.

Smoking status in the first line treatment of advanced EGFR-mutant non-small cell lung cancer : a network meta-analysis of randomized controlled trials

Xie, TJ¹; Liu, CC²; Xu, ZY³; Zou, ZH⁴; Zhu, YX⁵; Li, JL⁶; Wang, L⁷; Xing, PY⁸.

Review question / Objective: Patient: Patients with non-small cell lung cancer(NSCLC) harboring epidermal growth factor receptor(EGFR) mutation; Intervention: Tyrosine kinase inhibitors(TKIs) with or without anti-VEGF; Comparison: TKIs or chemotherapy; Outcomes: OS, PFS; Study design: Randomized controlled trial.

Condition being studied: Non-small cell lung cancer (NSCLC) is one of the most common malignancies with poor prognosis and low 5-year survival rate. Recently, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has improved the clinical prognosis of NSCLC patients, especially lung adenocarcinoma patients with EGFR mutation. There are a wide variety of EGFR-TKIs currently in common use, and studies of these drugs have included populations with many different baseline characteristics, including smoking status. Therefore, this meta-analysis will analyze which kind of EGFR-TKIs can achieve the optimal prognosis in smoking and non-smoking patients, respectively.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 17 October 2020 and was last updated on 17 October 2020 (registration number INPLASY2020100060).

INTRODUCTION

Review question / Objective: Patient: Patients with non-small cell lung cancer(NSCLC) harboring epidermal growth factor receptor(EGFR) mutation; Intervention: Tyrosine kinase inhibitors

(TKIs) with or without anti-VEGF; Comparison: TKIs or chemotherapy; Outcomes: OS, PFS; Study design: Randomized controlled trial.

Condition being studied: Non-small cell lung cancer(NSCLC) is one of the most

common malignancies with poor prognosis and low 5-year survival rate. Recently, epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) has improved the clinical prognosis of NSCLC patients, especially lung adenocarcinoma patients with EGFR mutation. There are a wide variety of EGFR-TKIs currently in common use, and studies of these drugs have included populations with many different baseline characteristics, including smoking status. Therefore, this meta-analysis will analyze which kind of EGFR-TKIs can achieve the optimal prognosis in smoking and non-smoking patients, respectively.

METHODS

Participant or population: Patients with non-small cell lung cancer(NSCLC) harboring epidermal growth factor receptor(EGFR) mutation.

Intervention: Tyrosine kinase inhibitors (TKIs) with or without anti-VEGF.

Comparator: Tyrosine kinase inhibitors (TKIs) or chemotherapy.

Study designs to be included: Any randomized controlled trials(RCTs) involving OS, PFS of TKIs for treating EGFR positive NSCLC will be included.

Eligibility criteria: 1. The searching language is English; 2. All included studies were RCTs and had clinical outcomes, such as OS, PFS; 3. All included studies had clear baseline characteristics of patients and EGFR mutation status; 4. All included studies included subgroup-analysis data required for meta-analysis.

Information sources: Pubmed, Embase, Cochrane Library, ASCO.org, ESMO.org.

Main outcome(s): OS, PFS.

Quality assessment / Risk of bias analysis: We assessed the methodological quality of the included studies by using the Cochrane Collaboration's tool for assessing risk of bias. R(ver. 3.6.3) and STATA(ver16.0) were used to assess the quality of studies.

Strategy of data synthesis: We synthesized all direct and indirect evidence to compare the efficacy of different treatments, reported as hazard ratios for survival outcomes (progression free survival and overall survival) along with corresponding 95% confidential intervals. The primary outcome was progression free survival. Secondary outcomes were overall survival. We generated network plots for different outcomes of different targeted patients to illustrate the geometries, to clarify which treatments were compared directly or indirectly in the included studies. We did frequentist, fixed effects, pairwise meta-analysis on head-to-head comparisons based on two or more trials. We assessed heterogeneity between studies using the Q test and I² statistic within a visual forest plot. Statistical significance was set at a P value of 0.05. Heterogeneity was considered low, moderate, or high for estimated I² values under 25%, between 25% and 50%, and over 50%, respectively.

Subgroup analysis: We will consider subgroups such as study design.

Sensibility analysis: If significant heterogeneity exists, sensitivity analysis will be performed.

Country(ies) involved: China.

Keywords: NSCLC; TKIs; Network meta-analysis; Smoking status.

Contributions of each author:

Author 1 - Tongji Xie.

Author 2 - Chengcheng Liu.

Author 3 - Ziyi Xu.

Author 4 - Zihua Zou.

Author 5 - Yixiang Zhu.

Author 6 - Junling Li.

Author 7 - Le Wang.

Author 8 - Puyuan Xing.